EAACI Congress 2025

Back

13 - 16 June 2025 Glasgow, United Kingdom

OAS13 - Diagnosis and management of Eosinophilic Esophagitis

Sunday 15 Jun, 09:00 AM - 10:30 AM Glasgow, United Kingdom

Carron 1 Oral Abstract Sessions

09:00

Dupilumab Treatment Reduces IgE Levels in Patients Aged 2 to 17 Years With Atopic Dermatitis, Asthma, and Eosinophilic Esophagitis

Lisa Beck (United States of America)

09:12

Disrupted mucosal vascular barrier in adult patients with eosinophilic esophagitis

Carlo Maria Rossi (Italy)

09:24

Dupilumab Is Efficacious in Children Aged 1–11 Years Weighing ≥15 kg With Eosinophilic Esophagitis Irrespective of Individual Atopic Comorbidities: 16-Week Results From the Phase 3 EoE KIDS Study

Antonella Cianferoni (United States of America)

09:36

Dupilumab decreases the number of days with dysphagia in adult and adolescent patients with eosinophilic esophagitis: post hoc analysis of LIBERTY EoE TREET study

Francesca Racca (Italy)

09:48

Cross-Sectional Real-World Survey of Adult Patients with Eosinophilic Oesophagitis: Symptom Burden and Adaptive Behaviours

Mirna Chehade (United States of America)

10:00

Outcomes of food reintroduction and identification of food triggers in paediatric eosinophilic gastritis

Wenyin Loh (Singapore)

10:12

Reference values of Eosinophilic Derived-Neurotoxin in blood of adults: reasons to use EDTA plasma

Douwe de Boer (Netherlands)